美国Corrona登记研究中强直性脊柱炎与非放射学中轴型脊柱关节炎患者的特征分析
本研究基于美国Corrona银屑病关节炎/脊柱关节炎登记系统,纳入407例中轴型脊柱关节炎患者(强直性脊柱炎310例,非放射学中轴型脊柱关节炎97例),比较两组人口学、临床特征、患者报告结局和治疗特征。结果显示两组疾病负担(疾病活动度、功能、生活质量、疼痛、疲劳、缺勤和工作效率损失)及生物制剂使用模式相似(均P>0.05)。
要点
- 非放射学中轴型脊柱关节炎患者较年轻,症状持续时间有缩短趋势。
- 两组疾病活动度、功能、生活质量、疼痛、疲劳及工作效率损失相似(均P>0.05)。
- 两组既往和当前生物制剂DMARDs使用比例相似(均P>0.05)。
核心结论
- 这是美国首个全国性研究,描述强直性脊柱炎与非放射学中轴型脊柱关节炎患者的特征。
- 与美国以外研究一致,非放射学中轴型脊柱关节炎与强直性脊柱炎患者疾病负担程度相当,临床实践中治疗模式相似。
研究设计与样本
- 基于美国Corrona银屑病关节炎/脊柱关节炎登记系统,在入组时评估患者的人口学、临床特征、患者报告结局和治疗特征。
- 强直性脊柱炎定义:符合1984年修订版纽约标准;非放射学中轴型脊柱关节炎定义:所有其他不符合放射学标准的中轴型脊柱关节炎患者。
- 共纳入407例中轴型脊柱关节炎患者,其中强直性脊柱炎310例,非放射学中轴型脊柱关节炎97例。
主要发现
- 非放射学中轴型脊柱关节炎患者较年轻,症状持续时间有缩短趋势。
- 两组疾病活动度、功能、生活质量、疼痛、疲劳、缺勤和工作效率损失比较均P>0.05。
- 非放射学中轴型脊柱关节炎组与强直性脊柱炎组既往生物制剂DMARDs使用比例分别为74.2%和64.8%(P>0.05)。
- 非放射学中轴型脊柱关节炎组与强直性脊柱炎组当前生物制剂DMARDs使用比例分别为63.9%和61.3%(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the characteristics of patients with ankylosing spondylitis (AS) and patients with nonradiographic axial spondyloarthritis (SpA) in the US. METHODS: Demographics, clinical characteristics, patient-reported outcomes, and treatment characteristics of patients with AS and those with nonradiographic axial SpA were assessed at the time of enrollment in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Patients with AS were defined as those who fulfilled the 1984 modified New York criteria for AS; patients with nonradiographic axial SpA were defined as all other patients with axial SpA who did not fulfill the radiology criterion. RESULTS: Of the 407 patients with a diagnosis of axial SpA who were included in this study, 310 had AS, and 97 had nonradiographic axial SpA. Although patients with nonradiographic axial SpA were younger and showed a trend toward a shorter symptom duration, the nonradiographic axial SpA and AS groups shared a similar disease burden, as reflected by comparisons of disease activity and function, quality of life, pain, fatigue, job absenteeism, and loss of work productivity (all P > 0.05). The proportions of patients with nonradiographic axial SpA and patients with AS who received prior biologic disease-modifying drugs (DMARDs) (74.2% and 64.8%, respectively) or were currently receiving biologic DMARDs (63.9% and 61.3%, respectively) were also similar (P > 0.05). CONCLUSION: This was the first nationwide study to characterize patients with AS and nonradiographic axial SpA in the US. Consistent with studies published outside of the US, this study showed that patients with nonradiographic axial SpA and patients with AS shared a comparable degree of disease burden and had similar treatment patterns in clinical practice.
引用
- Mease PJ, Heijde DV, Karki C, et al. Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry. Arthritis Care Res (Hoboken). 2018. PMID: 29409123. doi:10.1002/acr.23534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。